Cost Evaluation Analysis of Genetic Testing and Tailored Adjuvant Imatinib in Patients With Resected High-Risk GI Stromal Tumors: The Brazilian Perspective.

Bruna Bianca Lopes David Pedro Nazareth Aguiar Matheus Costa E Silva Rodrigo Dienstmann Carlos Gil Ferreira Cesar Serrano

Published in: JCO global oncology (2023)

The molecularly tailored adjuvant imatinib reduced costs considering the COPE of available NGS tests for both the public and private Brazilian health care systems.

Keyphrases

healthcare
chronic myeloid leukemia
early stage
smoking cessation
bone marrow
lymph node
health insurance
emergency department